首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1569472

肺炎檢測市場規模、佔有率和成長分析：按產品類型、類型、最終用戶、地區分類 - 產業預測，2024-2031 年

Pneumonia Testing Market Size, Share, Growth Analysis, By Product Type, By Type, By End-user, By Region - Industry Forecast 2024-2031

出版日期: 2024年10月13日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年肺炎檢測的全球市場規模為5.25億美元，從2023年的5.5965億美元增至2031年的9.332億美元，並且在預測期內（2024-2031年）將以複合年成長率6.6%成長。

肺炎檢測市場受到各種動態驅動和阻礙因素因素的影響，形成其成長軌跡。肺炎發病率不斷上升，特別是在老齡化人口和慢性疾病患者中，加上空氣污染水平不斷上升，大大推動了對有效診斷解決方案的需求。同時，人們對早期診斷和治療的必要性的認知不斷提高，尤其是兒童和老年人等高風險族群，這進一步推動了市場的發展。診斷技術的進步，包括分子診斷和就地檢驗，對於提高檢測的準確性和可近性至關重要，特別是在服務不足的社區。然而，挑戰仍然存在，例如經濟限制限制了某些地區獲得先進診斷的機會，嚴格的監管核准可能會抑制產品創新和市場進入。儘管存在這些障礙，但對預防性醫療保健的更多關注以及提高負擔能力和準確性的持續研究預計將在可預見的未來維持市場勢頭。同樣，由於對氣候變遷的擔憂以及對清潔能源來源的需求，生質能發電產業正在經歷顯著成長。有機生質能提供了一種永續的能源解決方案，可促進能源安全，同時減少對進口的依賴。支持可再生能源措施的政府政策也正在推動全球生質能計劃的投資。然而，市場面臨來自其他產業對生質能原料的競爭、潛在的負面環境影響、物流障礙以及能源轉換過程的技術限制等挑戰。應對這些挑戰對於釋放生質能在全球能源格局中的全部潛力至關重要。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Thermo Fisher Scientific Inc.（US）
Quidel Corporation（US）
Becton, Dickinson, and Company（US）
Meridian Bioscience, Inc.（US）
Qiagen NV（Netherlands）
bioMerieux SA（France）
Bio-Rad Laboratories Inc.（US）
Cardinal Health Inc.（US）
Hologic Inc.（US）
La Roche Ltd.（Switzerland）
Abbott Laboratories（US）
Quest Diagnostics（US）
Luminex Corporation（US）
F. Hoffmann-La Roche Ltd.（Switzerland）
Agena Bioscience, Inc.（US）
Roche Diagnostics（Switzerland）
Grifols, SA（Spain）
PerkinElmer, Inc.（US）
Genoa Healthcare, LLC（US）
SeraCare Life Sciences, Inc.（US）
Randox Laboratories Ltd.（UK）
Acon Laboratories, Inc.（US）

簡介目錄

Product Code: SQMIG35D2250

Global Pneumonia Testing Market size was valued at USD 525 million in 2022 and is poised to grow from USD 559.65 million in 2023 to USD 933.2 million by 2031, growing at a CAGR of 6.60% during the forecast period (2024-2031).

The pneumonia testing market is influenced by various dynamic drivers and constraints that shape its growth trajectory. Increasing pneumonia prevalence, particularly among aging populations and those with chronic diseases, alongside rising air pollution levels, significantly propels demand for effective diagnostic solutions. Alongside this, heightened awareness of the need for early diagnosis and treatment in at-risk groups, particularly children and the elderly, further drives the market. Technological advancements in diagnostic methods-including molecular diagnostics and point-of-care testing-are crucial in enhancing testing accuracy and accessibility, particularly in underserved areas. However, challenges such as economic limitations in certain regions restrict access to advanced diagnostics, while stringent regulatory approvals can impede product innovation and market entry. Despite these hurdles, a growing focus on preventive healthcare and ongoing research to improve affordability and accuracy is expected to sustain market momentum in the foreseeable future. Similarly, the biomass power generation sector is experiencing significant growth, fueled by the need for cleaner energy sources amid climate change concerns. Biomass, sourced from organic materials, presents a sustainable energy solution that promotes energy security while reducing reliance on imports. Government policies supporting renewable energy initiatives also bolster investment in biomass projects globally. Nevertheless, the market faces challenges, including competition for biomass feedstock with other industries, the potential for negative environmental impacts, logistical hurdles, and technological limitations in energy conversion processes. Addressing these challenges will be crucial for unlocking the full potential of biomass in the global energy landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the global pneumonia testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

global pneumonia testing Market Segmental Analysis

Global Pneumonia Testing Market is segmented by Product Type, Type, End-user, and region. Based on Product Type, the market is segmented into Instruments, Reagents & Consumables. Based on Type, the market is segmented into Streptococcus-based, Legionella-based, Chlamydophila-based, Viral Pneumonia-based, Mycoplasma Pneumonia-based, Others. Based on End-user, the market is segmented into Hospitals & Clinics, Diagnostic Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the global pneumonia testing Market

Demographic trends represent a significant market driver for the global pneumonia testing market, as aging populations worldwide are witnessing a rise in the incidence of pneumonia. With increased life expectancy, many elderly individuals face health challenges, including compromised immune systems that heighten their vulnerability to respiratory infections like pneumonia. This demographic shift not only amplifies the need for accurate and timely testing but also drives the demand for innovative diagnostic solutions tailored to this age group. Consequently, healthcare providers are increasingly focusing on enhancing pneumonia diagnostic capabilities, establishing a robust market for pneumonia testing technologies and services.

Restraints in the global pneumonia testing Market

One of the key market restraints for the global pneumonia testing market is the economic constraints experienced by healthcare systems, particularly in low- and middle-income regions. Limited healthcare budgets often hinder the ability of institutions to invest in advanced diagnostic technologies, which are essential for effective pneumonia testing. Disparities in healthcare access further exacerbate the issue, as marginalized communities may lack the necessary facilities and resources to implement comprehensive testing programs. These economic challenges lead to a slower adoption of pneumonia testing solutions, ultimately stalling market growth and limiting the availability of early diagnosis and treatment for this serious illness.

Market Trends of the global pneumonia testing Market

The global pneumonia testing market is experiencing a significant shift towards point-of-care testing, largely fueled by the demand for rapid diagnostics in emergency and primary care environments. With an increasing emphasis on early disease detection and prompt treatment initiation, point-of-care tests provide healthcare professionals with the capability to deliver immediate results, enhancing clinical decision-making and ultimately improving patient outcomes. This trend is further supported by technological advancements in diagnostic tools and an expanding focus on personalized healthcare solutions, thereby reshaping the landscape of pneumonia management and positioning point-of-care testing as a pivotal component of contemporary healthcare strategies.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Degree of Competition
PESTEL Analysis

Pneumonia Testing Market by Product Type

Market Overview
Instruments
Reagents & Consumables

Pneumonia Testing Market by Type

Market Overview
Streptococcus-based
Legionella-based
Chlamydophila-based
Viral Pneumonia-based
Mycoplasma Pneumonia-based
Others

Pneumonia Testing Market by End-user

Market Overview
Hospitals & Clinics
Diagnostic Centers
Others

Pneumonia Testing Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quidel Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson, and Company (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Meridian Bioscience, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Qiagen N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
bioMerieux SA (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cardinal Health Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Quest Diagnostics (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Luminex Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agena Bioscience, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Diagnostics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols, S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PerkinElmer, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Genoa Healthcare, LLC (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SeraCare Life Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Randox Laboratories Ltd. (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Acon Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments